HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1110v1 30/11/2922    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Brignardello, E. Articles by Boccuzzi, G. Search for Related Content PubMed PubMed Citation Articles by Brignardello, E. Articles by Boccuzzi, G. Social Bookmarking                What's this?

Dehydroepiandrosterone Administration Counteracts Oxidative Imbalance and Advanced Glycation End Product Formation in Type 2 Diabetic Patients

¹ Oncological Endocrinology Unit, San Giovanni Battista Hospital, Turin, Italy
² Department of Internal Medicine, University of Turin, Turin, Italy
³ Department of Experimental Medicine and Oncology, University of Turin, Turin, Italy
⁴ Department of Clinical Pathophysiology, University of Turin, Turin, Italy

Address correspondence and reprint requests to Prof. Giuseppe Boccuzzi, Dipartimento di Fisiopatologia Clinica, Via Genova, 3-10126 Torino, Italy. E-mail: giuseppe.boccuzzi{at}unito.it

OBJECTIVE—Dehydroepiandrosterone (DHEA) has been shown to prevent oxidative stress in several in vivo and in vitro models. This study aimed to evaluate the effects of DHEA administration on oxidative stress, pentosidine concentration, and tumor necrosis factor (TNF)-/TNF- receptor system activity in patients with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Twenty patients were enrolled in the study and randomly assigned to the DHEA (n = 10) or placebo (n = 10) group. Twenty healthy sex- and age-matched subjects with normal glucose levels served as control subjects. DHEA was given as a single daily dose of 50 mg for 12 weeks.

RESULTS—Oxidative stress parameters were significantly higher in diabetic patients versus control subjects. Pentosidine levels, as well as soluble TNF receptor (sTNF-R)I and sTNF-RII, were also higher in diabetic patients. After DHEA, plasma levels of reactive oxygen species and hydroxynonenal dropped by 53 and 47%, respectively, whereas the nonenzymatic antioxidants glutathione and vitamin E increased (+38 and +76%, respectively). The same changes in oxidative parameters were detected in peripheral blood mononuclear cells (PBMCs). DHEA treatment also induced a marked decrease of pentosidine plasma concentration in diabetic patients (–50%). Moreover, the TNF-/TNF- receptor system was shown to be less activated after DHEA treatment, in both plasma and PBMCs.

CONCLUSIONS—Data indicate that DHEA treatment ameliorates the oxidative imbalance induced by hyperglycemia, downregulates the TNF-/TNF- receptor system, and prevents advanced glycation end product formation, suggesting a beneficial effect on the onset and/or progression of chronic complications in type 2 diabetic patients.

Abbreviations: AGE, advanced glycation end product • DHEA, dehydroepiandrosterone • DHEAS, DHEA sulfate • GSH, glutathione • HNE, hydroxynonenal • HOMA, homeostasis model assessment • PBMC, peripheral blood mononuclear cell • ROS, reactive oxygen species • sTNF-R, soluble tumor necrosis factor receptor • TNF, tumor necrosis factor

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?